Genomics Medicine Ireland (GMI) has announced the establishment of a Strategic Advisory Board that will work collaboratively with GMI in shaping the company’s strategy for the application of large-scale genomics population studies on the island of Ireland, in addition to providing input and advice on the multi-disciplinary integration of genomics into the Irish healthcare system. The board, which met for the first time last month, comprises members from across the medical and research communities both in Ireland and internationally.
Dr. Anne Jones, CEO of GMI, commented, “I am excited with the high calibre of individuals who have agreed to be a part of this board. Collaboration is a core element of what we do in GMI, given that we interact with medical professionals, researchers, institutions, patient advocacy groups, and many others on a daily basis. The Strategic Advisory Board is a natural extension of this and will assist us in our overarching objective of improving patient lives through genomics, and ensuring the best possible implementation of this revolutionary science in Ireland.”
The Genomics Medicine Ireland Strategic Advisory Board will draw on the experience of individuals from the healthcare system, academic institutions, and the private sector. It is chaired by Dr. Anne Jones and will meet quarterly. Members include:
- Owen Patrick Smith CBE, Executive Director, Ireland East Hospital Group Genomics Directorate and Professor of Paediatric and Adolescent Medicine at University College Dublin
- Sarah O’Connor, CEO of the Asthma Society of Ireland
- Michael Farrell, Neuropathologist, Beaumont Hospital
- Frank O’Donnell, Public Sector Lead, Microsoft Ireland
- Mary Shire, Senior Executive, University of Limerick
- Jim Sullivan, Venture Partner, Orbimed and former Vice President of Global Discovery at AbbVie
- John O’Brien, former CEO at St. James’s Hospital
- Joris Veltman, Director of the Institute of Genetic Medicine, Newcastle University
GMI is positioning Ireland at the forefront of genomic research though building a high-quality genomic database which will include data from approximately 10% of the Irish population, including both patients with various disease conditions and participants from the general population. This information, linked to comprehensive phenotype data, will help in the development of new diagnostic techniques and in understanding cell and system biology with the aim to discover better disease treatments. The company has already enjoyed early success in establishing genomic research studies on the island of Ireland, including: Multiple Sclerosis, Alzheimer’s, Inflammatory Bowel Disease, Ankylosing Spondylitis, Asthma, and Rare Diseases, with a total of 60 disease areas targeted.